Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 17/20 | 0.70 |
| ▸ | EPAS1 | Q99814 | 17/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934508 | 0.77 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL29517160 | 0.75 | HIF1A (0.60) | HIF1AEPAS1MEN1LMNAKMT2A | |
| Achyrofuran SCHEMBL505137 | 0.74 | HIF1A (0.57) | HIF1AEPAS1MEN1LMNATP53 | |
| Achyrofuran SCHEMBL29375603 | 0.74 | HIF1A (0.57) | HIF1AEPAS1MEN1LMNATP53 | |
| SCHEMBL29517117 | 0.67 | HIF1A (0.70) | HIF1AEPAS1MEN1LMNATP53 | |
| SCHEMBL29520661 | 0.67 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL7028753 | 0.65 | HIF1A (0.52) | HIF1AEPAS1MEN1MAPTMAPK1 | |
| SCHEMBL30927109 | 0.64 | HIF1A (0.71) | HIF1AEPAS1MEN1LMNAKMT2A | |
| SCHEMBL5914907 | 0.62 | ALDH1A1 (0.53) | HIF1AEPAS1MEN1MAPTMAPK1 | |
| SCHEMBL15501063 | 0.62 | HIF1A (0.51) | HIF1AEPAS1MEN1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250311723-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | IMPELLO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20230200385-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | IMPELLO BIOSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4188090-A2 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | Impello Biosciences, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11638427-B2 | Methods and compositions for altering secondary metabolites in plants | IMPELLO BIOSCIENCES, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20220079150-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | IMPELLO BIOSCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2022026613-A2 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | IMPELLO BIOSCIENCES, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079150-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | ERG28, AHCY, BROX | HIF1A 3054/4885EPAS1 2165/4885MEN1 2970/4885 |
| US-20250311723-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | ERG28, AHCY, BROX | HIF1A 3054/4885EPAS1 2165/4885MEN1 2970/4885 |
| US-11638427-B2 | Methods and compositions for altering secondary metabolites in plants | ERG28, AHCY, BROX | HIF1A 3054/4885EPAS1 2165/4885MEN1 2970/4885 |
| US-20230200385-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | ERG28, AHCY, BROX | HIF1A 3054/4885EPAS1 2165/4885MEN1 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.